Direkt zum Inhalt
Merck

Modeling retinitis pigmentosa through patient-derived retinal organoids.

STAR protocols (2021-04-27)
Yan-Ping Li, Wen-Li Deng, Zi-Bing Jin
ZUSAMMENFASSUNG

Human-induced pluripotent stem cells (hiPSCs) can be differentiated into well-structured retinal organoids. In this protocol, we successfully established 3D retinae from patient-derived hiPSCs and built the retinitis pigmentosa model in vitro. Moreover, mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene was corrected by CRISPR-Cas9 gene editing, which rescued the structure and function of the 3D retinae. For complete details on the use and execution of this protocol, please refer to Deng et al. (2018).

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dimethylsulfoxid, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Roche
DNAse I, from bovine pancreas
Sigma-Aldrich
Retinsäure, ≥98% (HPLC), powder
Sigma-Aldrich
MEM Nicht-essentielle Aminosäure-Lösung (100×), without L-glutamine, liquid, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
1-Thioglycerin, liquid, BioReagent, suitable for cell culture, ≥97% (titration)
Sigma-Aldrich
Anti-Opsin-Antikörper, rot/grün, Chemicon®, from rabbit
Sigma-Aldrich
G 418, suitable for plant cell culture, BioReagent
Sigma-Aldrich
Monoclonal Anti-Opsin antibody produced in mouse, clone RET-P1, ascites fluid